NewAmsterdam Pharma Co N.V. (NAMS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-24

NewAmsterdam Pharma Co N.V. (NAMS) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-24. 3 Form 8-K material event filings were reported by NAMS in the last 90 days. 1 Form 144 notices of proposed sale were filed for NAMS stock. InsiderAlpha tracks every NAMS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About NewAmsterdam Pharma Co N.V. (NAMS)

SEC CIK	0001936258

90-Day SEC Filing Activity

Form 4 filings (90d)	2
Form 8-K filings (90d)	3
Form 144 notices (90d)	1
Latest Form 4 filing	2026-06-24

Recent NAMS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-22	Kooij Louise Frederika	Chief Accounting Officer	M — Option exercise	25.0K	$10.90	$272K	SEC
2026-06-22	Kooij Louise Frederika	Chief Accounting Officer	S — Open-market sale	300	$30.73	$9K	SEC
2026-06-22	Kooij Louise Frederika	Chief Accounting Officer	M — Option exercise	15.0K	$11.90	$178K	SEC
2026-06-22	Kooij Louise Frederika	Chief Accounting Officer	S — Open-market sale	39.7K	$30.20	$1.20M	SEC
2026-05-26	Kooij Louise Frederika	Chief Accounting Officer	M — Option exercise	5.0K	$10.90	$54K	SEC
2026-05-26	Kooij Louise Frederika	Chief Accounting Officer	M — Option exercise	60.0K	$10.00	$600K	SEC
2026-05-26	Kooij Louise Frederika	Chief Accounting Officer	S — Open-market sale	65.0K	$35.69	$2.32M	SEC
2026-03-11	LANGE LOUIS G	Insider	S — Open-market sale	44.2K	$30.41	$1.34M	SEC
2026-03-11	LANGE LOUIS G	Insider	S — Open-market sale	446	$31.23	$14K	SEC
2026-03-09	LANGE LOUIS G	Insider	J — Other acquisition / disposition	44.6K	$11.50	$513K	SEC
2026-03-09	Kastelein Johannes Jacob Pieter	Chief Scientific Officer	M — Option exercise	101.4K	—	—	SEC
2026-03-09	Kastelein Johannes Jacob Pieter	Chief Scientific Officer	S — Open-market sale	101.4K	$30.29	$3.07M	SEC
2026-03-06	LANGE LOUIS G	Insider	S — Open-market sale	28.2K	$29.41	$829K	SEC
2026-03-06	Kastelein Johannes Jacob Pieter	Chief Scientific Officer	M — Option exercise	94.1K	—	—	SEC
2026-03-06	Kastelein Johannes Jacob Pieter	Chief Scientific Officer	S — Open-market sale	94.1K	$30.32	$2.85M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for NewAmsterdam Pharma Co N.V. (NAMS). Updated in real time as new filings are submitted to the SEC.

Most-Active NAMS Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Kooij Louise Frederika	11	$4.63M

Recent NAMS Form 8-K Material Events

2026-06-03 — Item 5.02, 5.07, 9.01 [SEC]
2026-05-07 — Item 2.02, 9.01 [SEC]
2026-04-24 — Item 5.02 · Leadership · neutral [SEC]
NewAmsterdam Pharma's Chief Accounting Officer Louise Kooij is departing effective August 31, 2026, following a separation agreement executed on April 24, 2026. Ms. Kooij will receive twelve months of base salary, a pro-rated 2026 bonus, accrued vacation, and extended vesting of
2026-03-02 — Item 7.01, 9.01 · Other · neutral [SEC]
NewAmsterdam Pharma posted an updated corporate investor presentation on its website on March 2, 2026. This is a routine disclosure of presentation materials for investor relations purposes, with no material business developments announced.
2026-02-18 — Item 2.02, 9.01 · Earnings · neutral [SEC]
NewAmsterdam Pharma issued a press release on February 18, 2026 announcing corporate updates and financial results for the year ended December 31, 2025. The actual content of the results and updates is not disclosed in this 8-K filing itself, only referenced as an exhibit.

Recent NAMS Form 144 Notices of Proposed Sale

2026-05-26 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-06-24 — Kooij Louise Frederika (Chief Accounting Officer)
2026-05-27 — Kooij Louise Frederika (Chief Accounting Officer)
2026-03-12 — LANGE LOUIS G (Insider)
2026-03-11 — LANGE LOUIS G (Insider)
2026-03-10 — Kastelein Johannes Jacob Pieter (Chief Scientific Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in NAMS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

NAMS Insider Trading — FAQ

What is the latest insider trade for NAMS?: NewAmsterdam Pharma Co N.V. (NAMS) had 2 insider filings in the last 90 days, with the most recent on 2026-06-24. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying NAMS stock?: 0 insider purchases of NAMS were filed in the last 90 days.
How many insiders are selling NAMS stock?: 0 insider sales of NAMS were filed in the last 90 days.
Where can I see NAMS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every NAMS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live NAMS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.